Last update 21 Nov 2024

Azasetron besylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(R)-Azasetron besylate, Arazasetron
+ [1]
Mechanism
5-HT3 receptor antagonists(Serotonin 3 (5-HT3) receptor antagonists), H4 receptor antagonists(Histamine H4 receptor antagonists)
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationPaediatric investigation plan (EU), Orphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC23H26ClN3O6S
InChIKeyGFVBDLIBPSGFDL-ZOWNYOTGSA-N
CAS Registry2025360-91-0

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hearing Loss, SuddenPreclinical
GB
15 Feb 2019
Hearing Loss, SuddenPreclinical
TR
15 Feb 2019
Hearing Loss, SuddenPreclinical
SK
15 Feb 2019
Hearing Loss, SuddenPreclinical
RS
15 Feb 2019
Hearing Loss, SuddenPreclinical
DE
15 Feb 2019
Hearing Loss, SuddenPreclinical
FR
15 Feb 2019
Hearing Loss, SuddenPreclinical
BG
15 Feb 2019
Hearing Loss, SuddenPreclinical
IL
15 Feb 2019
Hearing Loss, SuddenPreclinical
CA
15 Feb 2019
Hearing Loss, SuddenPreclinical
CZ
15 Feb 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
(gkcgjsycyp) = A good safety profile of SENS-401 is confirmed in the long term, with the drug being administered for the first time for an average duration of up to 23 weeks. wevsviiubd (fcmbzltglu )
Positive
20 Sep 2024
Phase 2
24
SENS-401 (Arazasetron)
(ewhejfdpxr) = zehmopkrzj vollsgzwyh (izznxhqnca )
Positive
15 Jul 2024
Control group
(ewhejfdpxr) = ffsodddiyy vollsgzwyh (izznxhqnca )
Phase 2
28
(urccgwfnok) = Presence of SENS-401 in the perilymph is confirmed in 100% of the patients sampled following cochlear implantation at levels compatible with potential therapeutic efficacy urdhsuqaor (xifrzlarov )
Met
Positive
11 Mar 2024
non-treated arm
Phase 2/3
115
(29 mg Dose Group)
buhodcszrf(yvwsehtlcw) = vwqonepjbe clhdqrvyqd (duzhlxgrnt, zbfmvhvozs - rufeelpgsr)
-
01 Mar 2023
(43.5 mg Dose Group)
buhodcszrf(yvwsehtlcw) = gxqzfyzlmf clhdqrvyqd (duzhlxgrnt, sdloaqifhf - vdybnravnw)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free